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Abstract 
 
Background 
Radiotherapy is an effective treatment for head and neck 
cancers  but  patients  often  experience  side  effects  which 
lead to weight loss.  Nutrition intervention in the form of 
counselling  or  oral  nutrition  support  (ONS)  is  frequently 
needed for these patients. For some patients, tube feeding 
is required to minimise weight loss during treatment.  
Method   
Data  was  collected  on  48  patients  who  received 
radiotherapy  to  the  head  and  neck  region  over  a  nine-
month period (June 2009–March 2010). Retrospective data 
collection was commenced in July 2010. Each patient’s Diet 
Therapy Department record was reviewed. Main outcome 
measures were: 1) type of nutrition support; 2) percentage 
weight change during treatment; and 3) Patient-Generated 
Subjective Global Assessment Global (PG-SGA) rating. 
Results 
On initial assessment 28 (77.8%) patients were classified as 
well nourished using the PG-SGA. Mean weight loss during 
radiotherapy was 5.74%. Risk factors for the need for ONS 
and  enteral  nutrition  support  (ENS)  were  older  age, 
presence  of  nutrition  impact  symptoms,  high-risk  tumour 
sites, advanced disease and  chemotherapy. No significant 
difference was shown in weight loss between ONS and ENS 
groups.  
Conclusion 
This study identified the need for early dietetic intervention 
for  high  nutritional  risk  groups  of  head  and  neck  cancer 
patients  to  prevent  significant  weight  loss.  Pre-treatment 
nutritional  status  did  not  influence  weight  loss  during 
treatment. ONS alone cannot prevent significant weight loss 
in patients with multiple nutrition impact symptoms. Early 
enteral  feeding  should  be  considered  in  this  group  of 
patients. 
Key Words 
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Background 
Malnutrition  is  commonly  seen  amongst  head  and  neck 
cancer patients. The incidence of malnutrition at diagnosis 
is  estimated  to  be  30–50%  of  all  patients.
1  The  cause  of 
malnutrition  at  diagnosis  amongst  head  and  neck  cancer 
patients  is  considered  multi-factorial  and  includes  both 
lifestyle factors such as smoking and heavy alcohol use and 
tumour factors.
2 The tumour itself can cause dysphagia and 
odynophagia  due  to  obstruction  contributing  to  reduced 
oral intake, while the catabolic effects of cancer cachexia 
lead to unintentional weight and muscle loss. 
 
Radiotherapy is an effective treatment for head and neck 
cancer.
3  During  radiation  treatment  patients  may 
experience dysphagia, odynophagia, mucositis, xerostomia, 
dysgeusia,  loss  of  appetite  and  fatigue.  Long  after  the 
radiation  treatment  is  completed  patients  may  develop 
trismus  (reduced  jaw  opening).  Concurrent 
chemoradiotherapy is associated with increased frequency 
of these acute side effects.
3 
 
Given  that  the  effectiveness  of  radiotherapy  treatment  is 
maximised  by  maintaining  the  radiation  treatment  as 
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scheduled,  unplanned  treatment  breaks  that  result  from 
severe mucositis, malnutrition or dehydration may lead to 
decreased  efficacy  of  treatment  and  thus  poorer  patient 
outcomes.
4 Weight loss is common in patients undergoing 
radiotherapy for head and neck cancer. It is also a critical 
factor  for  these  patients  as  significant  weight  loss 
contributes  to  poorer  quality  of  life  scores.
5-7  Significant 
weight  loss  also  correlates  with  treatment  interruptions, 
infections, mortality and hospital readmission rates.
8 
 
Nutrition  intervention  is  reported  to  positively  influence 
patient  outcomes  and  quality  of  life.
9  The  literature  also 
supports tube feeding via nasogastric tube or percutaneous 
endoscopic gastrostomy (PEG) as a means of minimising loss 
of weight in patients with locally advanced head and neck 
cancers receiving accelerated fractionation and concurrent 
chemoradiotherapy.
5,10,11 
 
To  date  there  have  been  no  studies  conducted  at  this 
tertiary hospital site to determine the extent of nutritional 
compromise and the supportive measures used in head and 
neck  cancer  patients  to  facilitate  adequate  nutrition 
throughout their treatment journey. 
 
The aims of this study were to determine: 1) the prevalence 
of malnutrition amongst a sample population of head and 
neck  cancer  patients  at  the  commencement  of  radiation 
therapy;  and  2)  the  proportion  of  patients  who  required 
ONS or ENS during their treatment. The use of ONS and ENS 
was  directly  compared  to  determine  the  factors  that 
precipitated their use and if they were equally as effective 
in  promoting  weight  stabilisation  among  patients 
experiencing weight loss.  
 
Method 
A  retrospective  chart  audit  was  conducted  on  patients 
presented  at  the  Head  and Neck  Cancer  Multidisciplinary 
Team  Meetings  at  Sir  Charles  Gairdner  Hospital  (SCGH) 
between 29 June 2009 and 29 March 2010. Retrospective 
data  collection  was  commenced  in  July  2010.  SCGH  is  a 
tertiary care hospital with specialist cancer care facilities. All 
patients receiving radiotherapy to the head and neck region 
at this facility are assessed by a dietitian, and a nutrition and 
diet therapy record is kept for each patient. The principal 
investigator,  a  dietitian  from  SCGH,  together  with  other 
dietitians at the hospital recorded weight, height, PG-SGA 
score and global rating and form of nutrition support as part 
of standard practice in their clinic notes. 
 
The  database  contained  125  patients  over  the  data 
collection  period.  Forty-eight  patients  randomly  selected 
from  the  database  by  a  nutrition  and  diet  therapy  staff 
member  comprised  the  sample.  Patients  were  selected 
from  the  database  if  they  met  inclusion  and  exclusion 
criteria  and  had  an  even  medical  record  number. 
Consecutive patients with even medical record numbers on 
the database were selected. The required sample size was 
60 but only 48 patients met the study criteria and had even 
medical record numbers.   
 
Inclusion criteria: 
  diagnosis of a head and neck cancer; 
  aged over 18 years; 
  completion  of  radiotherapy  as  all  or  part  of  curative 
intent treatment.  
 
Exclusion criteria: 
  received palliative radiotherapy; 
  recurrence of disease; 
  missing  demographic  data  (site,  staging,  treatment 
plan).  
 
Patient  consent  was  not  required  for  this  retrospective 
chart audit. The study was approved by the SCGH Quality & 
Safety Department and Curtin University Human Research 
Ethics Committee. 
 
Nutrition and Diet Therapy Department records from initial 
assessment and subsequent review consultations were then 
reviewed  using  an  audit  tool  (Appendix).  The  tool  was 
designed after considering data collection methods used in 
another  retrospective  chart  audit.
12  Data  was  extracted 
from the diet therapy record by the principal investigator 
(EJ) who is experienced at extracting information from the 
Nutrition  and  Diet  Therapy  Department  patient  notes.  A 
single investigator completed the audit to maintain intra-
rater  reliability  and  a  protocol  for  data  collection  was 
followed.  
 
The  scored  PG-SGA  includes  questions  relating  to  dietary 
intake,  the  presence  of  nutrition  impact  symptoms  and 
recent  weight  loss.
13  The  medical  history  and  physical 
examination components of the assessment are completed 
by a trained health professional. A score is awarded based 
on the impact that symptom has on nutritional status. The 
score is intended to guide the level of nutritional support 
that the patient needs. A global rating of well nourished, 
moderately  malnourished  and  severely  malnourished  can 
also be assigned based on the patients’ responses.  
 
Nutrition support was categorised into: 1) counselling alone; 
2) ONS; and 3) ENS. Patients were classified as counselling 
alone if they had dietary education for a high protein, high 
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symptoms  but  did  not  consume  specialised  nutrition 
supplements throughout their radiation treatment. Patients 
who  consumed  nutrition  supplements  orally  and  did  not 
receive tube feeding (nasogastric or PEG) were identified as 
the  ONS  group.  Patients  who  consumed  nutrition 
supplements via a feeding tube, contributing to all or part of 
their nutrient intake were identified as the ENS group. 
 
Tumours  had  been  grouped  in  stages  using  a  standard 
classification system
14 and this information  was extracted 
from the medical notes.  Stage IV disease is classified as the 
most advanced tumour stage. Body Mass Index (BMI) was 
calculated  and  classified  according  to  the  World  Health 
Organisation (WHO) criteria.
15,16 Percentage weight loss was 
calculated as weight (end radiotherapy)/weight (baseline) x 
100. Weight maintenance was classified as <5% weight loss 
from baseline. For data analysis the tumour site for each 
patient was  classified as either high risk or low risk. This 
classification was made based on literature review.
13,16 The 
high  risk  sites  included  the  oral  cavity,  oropharynx, 
nasopharynx, hypopharynx and larynx. Salivary glands and 
cutaneous primary cancers made up the low risk group. 
 
Data  was  analysed  using  SPSS  version  17.  Descriptive 
statistics  were  performed  to  determine  the  mean  and 
standard  deviation  for  demographic  data.  The  level  of 
statistical significance was set at a p-value of 0.05. Group 
means were compared by independent t-tests and the Chi-
squared test of association.  
 
Results  
Forty-eight  subjects  were  selected  for  audit.  Table  1 
summarises  the  baseline  characteristics  for  subjects 
receiving radiotherapy. The mean age of the sample was 63 
years (34-86 years). The majority of the subjects selected 
for this sample were males (n = 40). The mean BMI was 26.8 
kg/m
2 (SD ± 5.2) (n=34). A height measurement is required 
for the calculation of  BMI.  The BMI of 14 patients  (29%) 
could  not  be  calculated  because  their  height  was  not 
recorded.  Two  patients  (5.9%)  were  considered 
underweight (BMI < 18.5) at initial presentation. Thirty-six 
(75%)  subjects  were  assessed  using  the  PG-SGA.  Twelve 
(25%) subjects were not assessed with the PG-SGA due to 
time  constraints.  Twenty-eight  (78%)  of  the  patients 
assessed with the PG-SGA were considered well nourished.  
No  patient  received  a  PG-SGA  global  rating  of  severely 
malnourished. There is the potential for measurement error 
of the recorded data relating to the fact that different scales 
were  used  at  different  clinic  locations  and  it  was  not 
documented  if  patients  were/were  not  wearing  shoes. 
Dietitians have completed training in the PG-SGA to achieve 
consistency  amongst  practitioners  in  the  physical 
assessment component.  
 
Characteristic  Mean  
(n = 48) 
SD 
Age (years)  63  ± 13.3 
Weight (kg)  81.8  ± 20.4 
BMI (kg/m
2)  26.8  ± 5.2 
  n = 34  % 
<18.5  2  5.9 
18.5 - 24.9  11  32.4 
25 - 29.9  13  38.2 
>30  8  23.5 
     
PG-SGA
† global rating:  n = 36  % 
A: well nourished   28  77.8 
B: moderate malnutrition  8  22.2 
C: severe malnutrition  0  0 
     
Tumour Stage  n = 48  % 
I & II  6  12.5 
III & IV  22  45.8 
Unknown  20  41.7 
     
Tumour Site  n = 48  % 
High Risk  30  62.5 
Low Risk  13  27.1 
Unknown  5  10.4 
     
Treatment Modality  n = 48  % 
Radiation  15  31.2 
Surgery + Radiation  12  25 
Surgery + chemoradiation  2  4.2 
Chemoradiation  12  25 
Induction  chemo  + 
chemoradiation 
7  14.6 
     
† Patient Generated Subjective Global Assessment 
 
Table  1:  Baseline  characteristics  for  subjects  receiving 
radiotherapy to the head and neck region 
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Nutrition Support  n  Mean (%)  SD 
Counselling 
*  12  0.06  3.19 
Oral 
  26  7.61  5.74 
Enteral   8  8.94  6.67 
* = p < 0.05 
Table  2:  Mean  percentage  weight  loss  for  subjects  as 
categorised by type of dietetic intervention 
 
On  average,  subjects  lost  5.87%  (±  6.34%)  of  their  body 
weight during radiation treatment. Figure 1 summarises the 
degree  of  weight  loss  in  patients  receiving  radiotherapy. 
Eighteen  subjects  (37.5%)  maintained  their  weight  during 
radiation treatment. One-quarter of the sample had weight 
loss  of  >10%  body  weight  during  the  course  of  their 
radiation treatment. As shown in Table 2, subjects within 
the ONS and ENS groups lost significantly more weight than 
those who received counselling alone (p < 0.001).  
 
 
Figure 1: Degree of weight loss from commencement of 
radiotherapy for 48 subjects receiving radiotherapy to the 
head and neck region 
 
The mean age for patients requiring ENS was 70.75 years. 
Age was a statistically significant factor (p < 0.05) in those 
patients requiring enteral feeding in comparison to patients 
who  required  counselling  alone.  Figure  2  illustrates  the 
influence of the number of nutrition impact symptoms on 
the type of nutrition intervention provided. A statistically 
significant  difference  was  shown  between  number  of 
nutrition impact symptoms and type of nutrition support (p 
< 0.05). All eight patients who required enteral feeding had 
high  risk  (HR)  tumour  sites.  Patients  who  required  ONS 
throughout their treatment were more likely to have a high 
risk  tumour  site  in  comparison  to  a  low  risk  (LR)  (HR  = 
65.4%, LR = 17%). Seven of the eight patients (87.5%) who 
required  enteral  feeding  had  either  Stage  III  or  Stage  IV 
disease. Patients requiring ONS were more than four times 
more likely to have Stage III or IV cancers (n=14).  Three-
quarters  of  those  requiring  enteral  feeding  underwent 
chemotherapy as part of their treatment regime.  
 
Figure  2:  The  influence  of  number  of  nutrition  impact 
symptoms on type of nutrition intervention  
 
Discussion 
This  audit  has  demonstrated  a  lower  prevalence  of 
malnutrition  at  presentation  compared  with  previous 
studies.
1,8,17 This could reflect the exclusion of patients for 
palliative treatment in this audit. Palliative patients tend to 
have more advanced disease and therefore are more likely 
to  have  poorer  nutritional  status  due  to  the  size  and 
location of the tumour or from cancer cachexia. One study 
reported that 56% of malnourished patients in the sample 
had Stage III and IV disease,
18 however tumour stage was 
unreported  in  50%  of  the  current  study  sample.  Where 
tumour stage was known, 22 (78.5%) patients had Stage III 
and IV disease. At the time of diagnosis, critical weight loss 
has been more frequently observed in patients with cancer 
of the hypopharynx, oropharynx oral cavity, or supraglottic 
larynx.
17  The  lower  prevalence  of  malnutrition  at  initial 
presentation  in  this  sample  of  head  and  neck  cancer 
patients  may  also  reflect  current  trends  in  the  general 
population towards being overweight and obese with 61.7% 
of patients classified as overweight or obese.  This also has 
an impact on how much weight has to be lost before 5% 
loss is achieved. 
 
A  high  percentage  of  subjects  (25%)  from  this  sample 
experienced severe weight loss (>10% body weight) during 
their radiation treatment. Beaver et al reported that 32.7% 
of  their  sample  experienced  severe  weight  loss.
5  In  the 
same  study,  severe  weight  loss  in  patients  who  had 
prophylactic feeding tubes was 14% (n=4). Of note from the 
current audit is that mean weight loss between ONS and 
ENS  groups  did  not  differ  significantly.  This  is  likely  a 
reflection of the reactive approach to enteral feeding in the 
audited  hospital,  but  may  also  represent  a  difference 
between  the  patients  in  this  audit  and  those  previously 
reported in the literature. One study involving subjects of a 
comparable  age  and  gender  ratio  researched  weight  loss 
with Stage I and II head and neck cancer patients and found 
that 25% of the sample experienced greater than 5% weight  Australasian Medical Journal [AMJ 2012, 5, 1, 8-13] 
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loss,  in  comparison  to  the  62.5%  with  greater  than  5% 
weight loss in this sample.
19 
 
Whilst  this  study  did  not  look  directly  at  the  factors 
contributing  to  significant  weight  loss  in  this  population, 
many previous studies have investigated these factors. One 
study  reported  that  pre-treatment  determinations  of 
nutritional  status  or  dietary  habits  and  anthropometric 
measurements  were  not  predictive  of  weight  loss  during 
radiotherapy.
20  Studies  have  found  that  sex,  tumour  site 
and stage influenced critical weight loss during treatment.
19 
Early  disease  (Stage  I  or  II)  is  generally  compared  with 
advanced stages (III or IV), and the comparisons show that 
advanced  stage  head  and  neck  cancer  patients  are  more 
likely to experience  weight loss and consequently receive 
enteral nutrition. 
 
Mean weight loss in the present audit was 5.87%. Patients 
in the ONS and ENS groups of this audit had a mean weight 
loss of more than 8%. Capuano et al reported on the results 
of  their  nutritional  programme  designed  for  patients  to 
achieve and maintain their calculated energy and protein 
requirements.
8  They  observed  that  all  non-compliant 
patients continued to lose weight, whilst compliant patients 
did  not  lose  significant  amounts  of  weight.  In  practice, 
patients may find it difficult to be compliant if they have 
multiple  nutrition  impact  symptoms.
21  More  than  three 
nutrition impact symptoms were experienced by 29 patients 
(60.4%). Twenty-eight patients (62.5%) lost greater than 5% 
body weight during their treatment. This audit revealed a 
significant difference in weight loss between the counselling 
group  and  other  nutrition  support  groups.  However,  the 
group which received counselling alone had fewer nutrition 
impact symptoms and were therefore at a decreased risk of 
weight loss. Higher numbers of nutrition impact symptoms 
contribute to risk of weight loss and indicate the need for 
oral or enteral nutrition support.  
 
In this audit due to the small numbers and large number of 
categories  for  tumour  site,  for  statistical  analyses  the 
groups were divided into high-risk and low-risk categories to 
determine  if  this  influenced  the  need  for  oral  nutrition 
support. Whilst the results indicate a statistically significant 
difference between high-risk and low-risk tumour sites and 
the type of nutrition support required by patients (p < 0.05), 
it is not possible to  make inferences about more specific 
tumour  sites.  This  may  be  a  topic  for  future  studies  to 
consider. 
 
Treatment  type  was  investigated  for  its  relationship  with 
type  of  nutrition  support.  Radiation  combined  with 
chemotherapy was associated with a higher need for ONS 
and ENS (p < 0.05). This is consistent with the literature on 
combined  modality  treatment.  This  could  reflect  that 
chemotherapy is often given in conjunction with  high-risk 
tumour sites and not normally for low-risk salivary primary 
or cutaneous primary sites. The use of chemotherapy is a 
common  treatment  modality  in  patients  who  have  more 
advanced tumour stages. Those with early stage tumours 
are more likely to have single modality treatment.  
 
Conclusion 
This  study  has  identified  that  increasing  age,  high  risk 
tumour  site,  advanced  stage  disease  and  the  addition  of 
chemotherapy  are  risk  factors  for  weight  loss  during 
radiation treatment. These patients are more likely to need 
enteral feeding during treatment. Pre-treatment nutritional 
status did not influence weight loss during treatment in this 
study.  Therefore,  this  study  highlights  the  need  for  early 
identification  and  intensive  dietetic  intervention  for  high-
risk patients to prevent weight loss. It is also evident that 
ONS  alone  cannot  prevent  significant  weight  loss  in  the 
presence  of  multiple  nutrition  impact  symptoms.  It  is 
strongly recommended that early enteral feeding should be 
considered in this group of patients. The results from this 
study cannot be generalised for all head and neck cancer 
patients  due  to  the  small  sample  size.  Therefore,  we 
recommend that further studies with a larger sample size be 
undertaken. 
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Appendix: Audit Tool 
Patient code   
Sex   Male 
 Female 
Tumour Site   Oral Cavity 
 Oropharynx 
 Nasopharynx 
 Hypopharynx 
 Larynx 
  Paranasal  sinuses/nasal 
cavity 
 Salivary glands 
 Cutaneous primary 
 Unknown Primary 
TNM Stage  T:    N:    M: 
Treatment   Radiation 
 Surgery + Radiation 
 Chemoradiation 
 Surgery + chemoradiation 
  Induction  chemotherapy  + 
chemoradiation 
Weight (kg)  Baseline: 
End Radiotherapy: 
SGA Rating   A 
 B 
 C 
Body Mass Index (kg/m
2)   
Nutrition  Impact 
Symptoms 
 1 
 2 
 ≥ 3 
Nutrition Support   Counselling 
 Oral supplements 
 Enteral nutrition 
 